share_log

ChromaDex Co. (NASDAQ:CDXC) Insider Robert N. Fried Acquires 80,000 Shares

ChromaDex Co. (NASDAQ:CDXC) Insider Robert N. Fried Acquires 80,000 Shares

光明科技股份有限公司(納斯達克:CDXC) 內幕羅伯特·弗雷德收購 8 萬股股票
Defense World ·  2022/10/04 17:03

ChromaDex Co. (NASDAQ:CDXC – Get Rating) insider Robert N. Fried bought 80,000 shares of the stock in a transaction dated Friday, September 30th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $100,000.00. Following the acquisition, the insider now owns 972,314 shares in the company, valued at approximately $1,215,392.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

光明科技股份有限公司(納斯達克:CDXC — 獲得評級) 內幕羅伯特 ·N· 弗里德在 9 月 30 日星期五的交易中買了 80,000 股票。該股票以每股 1.25 美元的平均成本購買，總交易額為 100 萬美元。收購後，內幕人士現在擁有該公司的 972,314 股股份，價值約為 1,215,392.50 美元。該收購已在向證券交易委員會提交的文件中披露，該文件可通過以下方式獲得 證券交易所網站。

ChromaDex Stock Up 7.3 %

色度股票上漲 7.3%

Shares of NASDAQ:CDXC opened at $1.32 on Tuesday. ChromaDex Co. has a 12 month low of $1.15 and a 12 month high of $6.98. The company's 50-day moving average price is $1.55 and its two-hundred day moving average price is $1.83. The firm has a market cap of $90.21 million, a P/E ratio of -3.22 and a beta of 1.71.

納斯達克：CDXC 的股票在星期二開盤 1.32 美元。彩色有限公司擁有 12 個月低點，為 1.15 美元，創下 12 個月高點為 6.98 美元。該公司的 50 天移動平均價為 1.55 美元，其 200 日移動平均價為 1.83 美元。該公司的市值為 90.21 萬美元，市盈率為 -3.22，貝塔值為 1.71。

Get
取得
ChromaDex
色度
alerts:
警報：

ChromaDex (NASDAQ:CDXC – Get Rating) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative return on equity of 99.51% and a negative net margin of 41.01%. During the same quarter in the prior year, the business posted ($0.08) EPS. As a group, equities analysts predict that ChromaDex Co. will post -0.3 earnings per share for the current fiscal year.

色度 (NASDAQ: CDXC — 獲得評分) 上次發佈其季度收益數據，日期為 8 月 10 日（星期三）。該公司報告了本季度每股盈利（0.09 美元），缺少分析師的共識估計為（0.08 美元）（0.01 美元）。該公司的資產回報率為 99.51%，負淨利潤率為 41.01%。在上一年的同一季度，該業務每股盈利過帳（0.08 美元）。作為一個集團，股票分析師預測 Chromadex Co. 將在本財政年度公佈 -0.3 每股盈利。

Institutional Investors Weigh In On ChromaDex

機構投資者在色度上權衡

A number of hedge funds have recently added to or reduced their stakes in CDXC. Cubist Systematic Strategies LLC lifted its position in ChromaDex by 142.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 63,286 shares of the company's stock valued at $106,000 after purchasing an additional 37,163 shares during the period. Millennium Management LLC acquired a new position in ChromaDex during the 2nd quarter valued at about $1,275,000. Virtu Financial LLC acquired a new position in ChromaDex during the 2nd quarter valued at about $76,000. Renaissance Technologies LLC lifted its position in ChromaDex by 76.0% during the 2nd quarter. Renaissance Technologies LLC now owns 739,900 shares of the company's stock valued at $1,236,000 after purchasing an additional 319,399 shares during the period. Finally, Tieton Capital Management LLC lifted its position in ChromaDex by 59.9% during the 2nd quarter. Tieton Capital Management LLC now owns 2,285,015 shares of the company's stock valued at $3,816,000 after purchasing an additional 856,273 shares during the period. Institutional investors own 41.83% of the company's stock.
一些對沖基金最近增加或減少了他們在 CDXC 的股份。立體派系統策略有限責任公司在第二季度將其在 ChromaDeX 的地位提升了 142.3％。立體派系統策略有限責任公司現在擁有 63,286 股，價值為 106,000 美元的公司股票，價值在此期間額外購買 37,163 股後。千禧管理有限責任公司在第二季度收購了 Chromadex 的新職位，價值約為 1,275,000 美元。維圖金融有限責任公司在第二季度收購了 Chromadex 的新職位，價值約為 76,000 美元。文藝復興技術有限責任公司在第二季度提升了 76.0％ 在 Chromadex 的地位。文藝復興科技有限責任公司現在擁有該公司股票 739,900 股價值 1,236,000 美元的股票，在此期間額外購買 319,399 股股票。最後，鐵通資本管理有限責任公司在第二季度將其在 Chromadex 的地位提升了 59.9％。鐵通資本管理有限責任公司在期內額外購買 856,273 股股票後，擁有該公司股票 2,285,015 股價值 3,816,000 美元。機構投資者擁有公司股票的 41.83％。

Analyst Upgrades and Downgrades

分析師升級和降級

CDXC has been the topic of several analyst reports. HC Wainwright lowered their target price on shares of ChromaDex from $7.00 to $5.50 and set a "buy" rating on the stock in a report on Monday, August 29th. B. Riley lowered shares of ChromaDex from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $6.00 to $2.40 in a report on Thursday, August 11th. Finally, Oppenheimer lowered shares of ChromaDex from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 16th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $5.48.

CDXC 一直是幾個分析師報告的主題。韋萊特在 8 月 29 日（星期一）的一份報告中將該股票的目標價從 7.00 美元降至 5.50 美元，並在 8 月 29 日（星期一）的報告中設定了該股票的「買入」評級。B. 萊利將 ChromaDeX 的股票從「買入」評級下調至「中性」評級，並在 8 月 11 日（星期四）的一份報告中將該股票的目標價格從 6.00 美元降至 2.40 美元。最後，奧本海默在 8 月 16 日（星期二）的一份報告中，將 ChromaDeX 的股票從「跑贏大市」評級降低為「市場表現」評級。三位分析師對該股票進行了保持評級，兩位分析師對該股發出了買入評級。根據 MarketBeat 的數據，該公司的共識評級為「持有」，共識價格目標為 5.48 美元。

ChromaDex Company Profile

公司簡介

(Get Rating)

(取得評分)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Chromadex 公司是一家專注於健康老化的生物科學公司。該公司通過三個部分運營：消費品; 成分; 和分析參考標準和服務。研究煙酰胺腺嘌呤二核苷酸（NAD+），直接向消費者和經銷商提供含有其專有成分的成品膳食補充劑產品；並開發和商業化以專有成分為基礎的成分技術，並將這些成分作為原料供應給消費品製造商。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
  • Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
  • 3 Stocks Growing Their Businesses for 2023
  • China-Based EV Maker BYD Set For Big European, Japanese Expansion
  • Is Illumina Still the Gamechanger in Genomics Sequencing?
  • Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
  • 免費獲取有關色度（CDXC）的研究報告
  • 小型催化劑製藥是市場上最佳價格表現者之一
  • 3 股股票在 2023 年增長其業務
  • 中國電動汽車製造商比亞迪將進軍歐洲日本擴張
  • Illumina 仍然是基因組學測序中的遊戲改變者嗎？
  • 這是什麼使亞馬遜成為全部部件商務總結劍聖

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Chromadex 每日新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Chromadex 和相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論